Pfizer's HIV division hit by a supersonic boom.

First Pfizer had to deal with the maraviroc scandal and delayed FDA approval.

Now Ed Silverman is taking a second stab at this amazing story with juicy new revelations about how Pfizer's HIV sales force marketed Viracept.

If you are a visitor from the DoJ or FDA you really don't want to miss the second installment of this story, which includes lots of e-mails and names:

Go here.